

Regulatory Perspectives on Organ-on-Chip Models

Sonja Beken



Disclaimer:

The views expressed in this presentation are my personal views and may not be understood or quoted as being made on behalf of or reflecting the position of the Belgian Federal Agency for Medicines and Health Products or the European Medicines Agency







Let's set the scene

• Current preclinical testing paradigm established more than 3 decades ago


ta

- 48-70% of human toxicities in clinical trials predicted by preclinical studies (Olson et al 2000, Tamaki et al 2013)
- Old paradigm based largely on descriptive toxicology!
- Evolution to a more evidencebased mechanistic & translational paradigm
- A role for investigative toxicology
 - → combination of in silico, in vitro, in vivo, & clinical data
 - → use of innovative technologies & novel approaches

(Beilmann et al 2019, Pognan et al 2023)



EMA and the 3Rs: a long-standing commitment



The EMA 3Rs Working Party

Strategic and visible Working Party to monitor and supervise EMA's 3Rs activities

Multidisciplinary aspects of the 3Rs into a restricted core group

Composition:

Sonja Beken (Chair)	BE	FAGG-AFMPS-FAMHP	Human MPs - NCWP, Non-Clinical	
Sarah Adler-Flindt (Vice-Chair)	DE	Federal Office of Consumer Protection and Food Safety	Veterinary MPs - Non-Clinical	
Elisabeth Balks	DE	PEI	Veterinary MPs - Batch release	
Kathrine Just Andersen	DK	Danish Medicines Agency	Veterinary MPs - EWP-V, Non-Clinical and Clinical	
Camilla Svensson	SE	МРА	Human MPs - Non-Clinical	
Peter Theunissen	NL	MEB	Human MPs - Non-Clinical	

Support by:

- Operational Expert Groups & Drafting/Working Groups
- Non-Clinical and New Approach Methodologies European Specialised Expert Community
- EMA Scientific & administrative secretariat: 3Rs@ema.europa.eu
- Observers: European Commission, EURL ECVAM, EDQM





A 3RsWP with a vision to the future



- Strategic role in 3Rs through strengthened cooperation between all stakeholders and international partners
- Move non-clinical assessment from discovery toxicology towards regulatory use and acceptance of animal-free innovations or NAMs

 → hazard identification, toxicity prediction, ADME
 - modelling, disease modelling
- Follow-up of the 3Rs in batch release testing
- 3Rs Review and update of EMA guidelines & impact monitoring
- Focus on alternatives to the use of non-human primates



	EDICINES AGENCY				
26 January 2023 EMA/CHMP/14829/2023 Human Medicines Division					
Consolidated 3-year work plan for the Non-clinical domain including the priorities for 2023					
Domain Chairperson:	Bruno Sepodes				
Non-Clinical Working Party Chair:	Susanne Brendler-Schwaab				
Non-Clinical Working Party Vice-Chair:	Karen van Malderen				
3Rs Working Party Chair:	Sonja Beken				
3Rs Working Party Vice-Chair:	Sarah Adler-Flindt				

Work plan period: May 2022 - December 2024 (with a first review point after one year)





3RsWP Approach for Regulatory Acceptance of NAMs



Multistakeholder Workshops focused on requirements for regulatory acceptance (e.g. qualification) for NAMs






First EMA workshop on non-animal approaches in support of medicinal product development: challenges and opportunities for use of MPS



18 October 2018 EMA/CHMP/SWP/250438/2018 Human Medicines Research and Development Support Division

Meeting Report:

First EMA workshop on non-animal approaches in support of medicinal product development – challenges and opportunities for use of micro-physiological systems (EMA/CHMP/SWP/250438/2018) 5 October 2017, European Medicines Agency, London





2 break out sessions - 2 action lists Collaboration needed to :

- develop specific qualification guidance
- develop endpoint-specific performance standards incl. list of reference compounds per organ system and endpoint
- agree on stepwise approach for MPS using healthy versus diseased cells, taking into account specific COU
- Define 'gold standard' and discuss applicability of clinical biomarkers
- Identify the degree of flexibility to allow for continuous applicability of qualification criteria
 Data sharing as key for progress! Possible through EMA process of method qualification under voluntary

submission of data










Final Agenda Multistakeholder Kick-off Workshop:

Towards Qualification of MicroPhysiological Systems including Organ-on-Chip Models for Specific Contexts of Use to be Applied in the Pharmaceutical Area

Brussels, 30th January 2024



Pitching by

Industry/Method developers/Regulators Break-out sessions

- → practical recommendations for guidance
- → identification of further actions to foster progress towards regulatory acceptance

Some take home messages

- Need for data sharing
- Need for defined framework for voluntary data submission
- COU:

medicines and health product

- Think out of the box
- Impact on selection of gold standard and reference compounds
- Key role for IVIVE
- Model and modality considerations
- COU-qualification ≠ biological and technological characterization
- International harmonization is key



MPS/OoC: multiple contexts of use (COU)

Workshop Report

Building Blocks for a European Organ-on-Chip Roadmap

doi:10.14573/altex.1905221



Context of use	Disease area	Key tissue model	End user	
Disease mechanisms	Cancer	Tumor models	Biomedical researchers	
	Neurodegenerative diseases	Brain, BBB, neurons, retina	Clinicians Pharmaceutical industry	
	Cardiometabolic disorders	Heart, lung, liver, pancreas, vessels, adipose		
	Autoimmune diseases	Immune system, gut, pancreas, neurons, skin		
	Fibrosis	Connective tissues, lung, liver, kidney		
Drug efficacy	Cancer	All types	Industry: pharmaceutical,	
	Neurodegenerative diseases	Brain, BBB, neurons cosmetics Biomedical researchers		Focus on
	Cardiometabolic disorders	Heart, lung, liver, pancreas, vessels		COU-specifi qualification
	Autoimmune diseases	Immune system, gut		
	Fibrosis	Connective tissues, lung, liver, kidney		qualification
Drug toxicity	All types	ADME pathway (liver, kidney), barrier systems (gut, lung, BBB), heart, brain, immune system	Industry: pharmaceutical, cosmetics Biomedical researchers	
Personalized medicine: – Patient stratification (adverse effects, dynamics/resistance, identification of vulnerable population) – Companion diagnostics (responders, disease progression)	Cancer	All types	Pharmaceutical industry	
	Rare diseases	All types	Hospitals/clinicians	
	Systemic diseases Multi-organs		1	
	Autoimmune diseases	Immune system, gut		EU
progression)				belgium24.eu



COU: in need of inspiration?

SCIENCE MEDICINES ACTION SCIENCE MEDICINES ACTION	Торіс	Regulatory	/ provision	Animal testing requirements	Implemented 3Rs opportunities	Newly identified opportunities for 3Rs implementation
ober 2018 HMP/CVMP/3Rs/742466/2015 Ittee for Medicinal Products for Hup on the one of the one one of the one of the one o					(justified) dose level. No need for two-year carcinogenicity studies unless	
lection pap ulatory testing requirements for medicinal products for nan use and opportunities for implementation of the					concern. Use of a surrogate product in order to avoid use of non-human primates e.g. for reproductive toxicity testing, only if necessary	
	Safety pharmacology	Evaluation of Delayed Vent	lance on the Non-clinical the Potential for tricular Repolarisation Prolongation) by Human	In vivo and in vitro tests as complementary approaches to assess the potential for OT interval prolongation.	and scientifically justified. Integrated test strategy including <i>in vitro</i> tests (e.g. hERG assay) for assessment of QT- prolongation (ICH S7B).	ICH S7B guideline is currently schedule for revision. Aspects under consideratio will be advances in the science and methods as currently discussed in the
		Pharmaceutic ICH S7B)	als (CPMP/ICH/423/02;	"Core battery tests" of CNS		Comprehensive In vitro Pro-arrhythmia Assessment (CIPA) initiative.
harmonisation for better health		Note for Sale	/ Studies for Human als (CPMP/ICH/539/00;	and cardiovascular/respiratory function .	pharmacology parameters in repeated dose toxicity studies (see ICH S9).	endpoints: need for retrospective data analysis to expand concept beyond ICH S9.
			ance on Immunotoxicity uman Pharmaceuticals	Non-clinical assessment of unintended immune	Specific studies only when standard toxicity studies indicate	
ICH E14/S7B Implementation Working Group Clinical and Nonclinical Evaluation of QT/QTc Interval Prolongatio Potential Questions and Answers	n and Pr Desc • B		ctice conside		e S7B assays (hEf says & in vitro car	
E14/S7B Q&As Adopted on 21 February 2022 • Principles for proarrhythmia models						
	\rightarrow n	on-clir	ical data c	an be used to	o reduce clinica	al TQT studies

Development of COU-based qualification criteria Multistakeholder Workshops on NAMs/3Rs focused on requirements for regulatory acceptance (e.g. qualification)

Definition of regulatory acceptance criteria for NAMs for specific contexts
 of use

Scope

Inclusion of definition of critical 3Rsrelated terminology in the body of the guideline

Addition of annexes providing regulatory acceptance criteria for MPS/OoC models for specific contexts of use to be applied in the pharmaceutical area:

 liver-on-chip COU of predicting DIL
 heart-on-chip COU of safety pharmacology testing





12 October 2023 EMA/CHMP/CVMP/452614/2023 Committee for Medicinal Products for Human Use (CHMP) Committee for Veterinary Medicinal Products (CVMP)

- Concept paper on the revision of the Guideline on the
- 6 principles of regulatory acceptance of 3Rs (replacement,
- reduction, refinement) testing approaches
- 8 (EMA/CHMP/CVMP/JEG-3Rs/450091/2012)

Agreed by the 3Rs Working Party	June 2023
Agreed by the Non-Clinical Working Party	June 2023
Adopted by CHMP for release for consultation	12 October 2023
Adopted by CVMP for release for consultation	09 November 2023
Start of public consultation	20 November 2023
End of consultation (deadline for comments)	28 February 2024

10 11 12

13

14

Comments should be provided using this EUSurvey form. For any technical issues, please contact the EUSurvey Support .

Keywords Regulatory acceptance, qualification, microphysiological systems, organ-onchip, 3Rs, context of use, terminology

Qualification of NAMs

Development of COU-based qualification criteria

Qualification of NAMs • Multistakeholder Workshops on NAMs/3Rs focused on requirements for regulatory acceptance (e.g. qualification)

- Definition of regulatory acceptance criteria for NAMs/3Rs for specific contexts of use
- Creation of a global working group of regulators (harmonization!)

International 3Rs Regulatory Working Group:

- Kick-off meeting January 2024
- Drafting of Terms of Reference ongoing
- Participation by Australia, Canada, Europe, Japan, Switzerland & US.





Development of COU-based qualification criteria • Multistakeholder Workshops on NAMs/3Rs focused on requirements for regulatory acceptance (e.g. qualification)

- Definition of regulatory acceptance criteria for NAMs/3Rs for specific contexts of use
- Creation of a global working group of regulators (harmonization!)
- Collaboration with the EMA Methodology domain on modelling and simulation
- Support the early dialogue via the 3Rs Innovation Task Force

Qualification of NAMs





EMA's Innovation Task Force on 3R, <u>the</u> tool for early interaction with the regulatory network!

- NEW focus on regulatory acceptance of NAMs to replace the use of animals in the testing of medicines (3Rs):
 - encourage NAM development
 - accelerate NAM integration in the regulatory framework for the development and evaluation of medicines
- Important forum for early dialogue between regulators and stakeholders:
- informal guidance to method developers and end users in the need for, design and/or further elaboration of qualification package
- Stakeholders: SMEs, academics, researchers, research and publicprivate funded consortia, pharmaceutical industry
- ITF briefing meetings are confidential but notably increased uptake in relation to 3Rs in 2023
- ITF briefing meetings are free of charge










Development of COU-based qualification criteria Multistakeholder Workshops on NAMs/3Rs focused on requirements

for regulatory acceptance (e.g. qualification)

• Definition of regulatory acceptance criteria for NAMs/3Rs for specific contexts of use



Take Home Messages

- Early interaction & submission of NAM, including OoC data is encouraged → there are quick wins!
- Proactive approach: reflection on regulatory acceptance criteria for novel technologies such as organ-on chip ongoing
- Integration of NAM data in Weight-of –Evidence
 approaches
 - \rightarrow building evidence to define non-clinical programme (cfr ICH 511, ICH 51B(R1))
- Engagement & open dialogue with interested stakeholders is key







THANK YOU FOR YOUR ATTENTION









FOLLOW US ON OUR SOCIAL MEDIA



@EU2024BE



@EU2024BE



@EU2024BE



www.belgium24.eu







belgium24.eu

